Skip to main content
    T

    Tonix Pharmaceuticals Holding Corp (TNXP)

    Official site

    HEALTHCARE • BIOTECHNOLOGY • NASDAQ

    $2.88
    -0.13 (-4.32%)

    Market Cap: $58.49M

    Last updated: Nov 17, 2026 at 11:06 AM ET

    Tonix Pharmaceuticals Holding Corp (TNXP) Stock Forecast

    Updated Nov 17, 2026. Estimates and ratings come from consensus analyst data.

    Analysts expect Tonix Pharmaceuticals Holding (TNXP) to earn -$10.92 per share in the fiscal year ending Dec 31, 2026, on revenue of $57.51M. Of 4 analysts, 4 rate the stock Buy or Strong Buy, 0 Hold and 0 Sell or Strong Sell, for a consensus of Buy. Over the last 30 days, 1 estimate for the fiscal year ending Dec 31, 2026 was revised up and 0 down.

    Analyst Ratings

    Scoring Strong Buy as 1 and Strong Sell as 5, the 4 ratings average 2.00, inside the Buy band from 1.5 up to 2.5. Buy and Strong Buy make up 100% of the ratings.

    RatingAnalystsShare
    Strong Buy00.0%
    Buy4100.0%
    Hold00.0%
    Sell00.0%
    Strong Sell00.0%
    Consensus
    Buy
    Total analysts
    4

    Price Target

    Analyst price targets are part of paid GNG plans. See plans

    Annual Estimates

    From the first fiscal year below to the second, the EPS consensus shows a smaller loss and revenue estimates rise 96.2%.

    Fiscal year ending Dec 31, 2026
    -$10.92
    EPS consensus, revenue $57.51M
    Fiscal year ending Dec 31, 2027
    -$7.00
    EPS consensus, revenue $112.81M
    Next report
    Mar 10, 2027
    Estimated

    EPS range

    Revenue range

    Fiscal year endingEPS consensusEPS rangeEPS analystsRevenue consensusRevenue rangeRev. analysts
    Dec 31, 2026-$10.92-$11.10 to -$10.732$57.51M$57.22M to $57.80M2
    Dec 31, 2027-$7.00-$8.25 to -$4.863$112.81M$93.44M to $149.00M5

    Quarterly Estimates

    The EPS consensus falls from -$2.41 for the quarter ending Dec 31, 2026 to -$2.42 for the quarter ending Mar 31, 2027.

    EPS range

    Revenue range

    Quarter endingEPS consensusEPS rangeEPS analystsRevenue consensusRevenue rangeRev. analysts
    Dec 31, 2026-$2.41-$2.45 to -$2.398$20.70M$16.17M to $24.15M8
    Mar 31, 2027-$2.42-$2.42 to -$2.421$23.25M$17.50M to $29.00M2

    Estimate Revisions

    Across the 3 periods below, the last 30 days brought 2 upward and 2 downward EPS revisions.

    PeriodUp 30 daysDown 30 days
    Fiscal year ending Dec 31, 202610
    Fiscal year ending Dec 31, 202711
    Quarter ending Mar 31, 202701

    EPS Trend

    Over the last 90 days, the EPS consensus for the fiscal year ending Dec 31, 2026 has worsened from -$9.95.

    PeriodNow7 days ago30 days ago60 days ago90 days agoChange
    Fiscal year ending Dec 31, 2026-$10.92-$9.78-$9.95-$9.95-$9.95N/A
    Fiscal year ending Dec 31, 2027-$7.00-$6.82-$7.88-$7.88-$7.88N/A
    Quarter ending Mar 31, 2027-$2.42-$2.20-$2.20-$2.20-$2.20N/A

    Frequently Asked Questions About TNXP

    What is the TNXP stock forecast?

    Consensus analyst estimates put Tonix Pharmaceuticals Holding's EPS at -$10.92 for the fiscal year ending Dec 31, 2026, on revenue of $57.51M. The consensus rating from 4 analysts is Buy.

    How do analysts rate TNXP stock?

    Of 4 analysts covering Tonix Pharmaceuticals Holding, 0 rate it Strong Buy, 4 Buy, 0 Hold, 0 Sell and 0 Strong Sell, for a consensus of Buy.

    What EPS do analysts expect from TNXP next year?

    For the fiscal year ending Dec 31, 2026, the consensus EPS estimate is -$10.92, with estimates from -$11.10 to -$10.73 from 2 analysts. For the fiscal year ending Dec 31, 2027, the consensus EPS estimate is -$7.00, with estimates from -$8.25 to -$4.86 from 3 analysts.

    What revenue do analysts expect from Tonix Pharmaceuticals Holding next year?

    For the fiscal year ending Dec 31, 2026, the consensus revenue estimate is $57.51M, with estimates from $57.22M to $57.80M. For the fiscal year ending Dec 31, 2027, the consensus revenue estimate is $112.81M, with estimates from $93.44M to $149.00M.

    How many analysts cover TNXP?

    4 analysts rate Tonix Pharmaceuticals Holding stock, and 2 analysts estimate its EPS for the fiscal year ending Dec 31, 2026.